This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (15)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We describe 6 patients in whom areas of localized lipoatrophy developed at the injection site of glatiramer acetate, a drug currently used to treat remitting-relapsing multiple sclerosis. This adverse effect has never been reported before.

Report of a Case

The main clinical features of the 6 patients are given in Table 1. All patients showed asymptomatic, well-circumscribed skin depressions on the lateral side of the thighs and upper arms, the usual injection sites. The overlying skin did not exhibit inflammation, sclerosis, or hyperpigmentation. The lesions developed without any preceding inflammation and were about 12 to 60 cm² in area and 1 to 2 cm deep (Figure 1). Only occasionally was the glatiramer acetate injection followed by a transient burning sensation, mild pain, and wheals. Results of histopathological analysis showed a normal epidermis and a perivascular infiltrate with lymphocytes, neutrophils, and eosinophils throughout the dermis. There were fibroses of fat septa and . . . [Full Text of this Article]

Comment

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Strategies for managing the side effects of treatments for multiple sclerosis
Langer-Gould et al.
Neurology 2004;63:S35-S41.
ABSTRACT | FULL TEXT  

Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management
Frohman et al.
Mult Scler 2004;10:302-307.
ABSTRACT